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ABSTRACT

MEDICATION EXPENDITURE AND RESOURCE UTILIZATION AMONG
PATIENTS WITH MUSCULOSKELETAL DISORDERS: ANALYSIS OF 2007
MEDICAL EXPENDITURE PANEL SURVEY

By
Nipun Atreja
May 2012
Thesis Supervised by Dr. Khalid M. Kamal
Objective: To estimate the national prevalence and direct incremental expenditures of
musculoskeletal disorders (MSD's) using the 2007 Medical Expenditure Panel Survey
data.
Methods: A retrospective database analysis was conducted and individuals with MSD's
(ICD-9-CM codes 274.00; 710.00-738.00) were identified. Dependent variables were
total health care and other service category expenditures. The study utilized descriptive
and regression analyses.
Results: In 2007, the national prevalence of MSD's was 33 million with incremental
costs of $886.49 per person. The inpatient expenditures ($33,461.85) were the highest
cost component in MSD’s and the predictors of total health care expenditures were age,
marital status, and presence of the disease condition.
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Conclusion: The systematic assessment of MSD's and their associated incremental costs
to the society is essential in increasing the awareness of decision makers to implement
intervention strategies that are effective in lowering the disease incidence and in reducing
the overall cost of disease management.

Keywords: Musculoskeletal disorders, Medical Expenditures Panel Survey, incremental
health care expenditures, retrospective analysis, MSD’s, MEPS.
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CHAPTER ONE
INTRODUCTION
According to the Federal Bureau of Labor Statistics (BLS), musculoskeletal
disorders (MSD's) include injuries and disorders to muscles, nerves, tendons, ligaments,
joints, cartilage, and spinal discs.1 MSD's do not include injuries resulting from slips,
trips, falls, or similar accidents. The term MSD's identifies a large group of conditions
that result from body trauma and often involves the joint, muscle and bone. The major
disorders included under MSD's are diffuse diseases of connective tissue, arthropathies,
rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), spondylosis,
polymyalgia rheumatica, disorders of soft tissues, osteomyelitis periostitis, disorders of
bone and cartilage, and other acquired musculoskeletal deformities.

Epidemiology
The World Health Organization (WHO) scientific group have projected an
increase in the burden of MSD's in the developed and developing countries primarily due
to an increase in the overall life expectancy of the population and the subsequent increase
in non-communicable diseases.2 According to the Bone and Joint Organization
estimates, by 2030, individuals aged 65 years and older will double in size and the fastest
growth will be seen in individuals over 85 years of age. 3 This in turn would potentially
result in increased cases of MSD’s in the society.
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The prevalence of MSD's in the United States (US) ranged from 27.8% – 30.2%
between 1997 and 2000.4 The incidence of MSDs increased by 16% between 1996-1998
and 2002-2004 and in 2008, an estimated 110 million adults (approximately 50% of the
adult population) reported having a disabling musculoskeletal condition. Currently, one
in four individuals has a MSD that requires medical attention. 4
MSD’s are the leading occupational disease among all work-related illnesses not
only in the US but also in Nordic countries and Japan. 3 An estimated 40% of all upper
extremity disorders in the employed population of the US are due to occupational
exposure and the prevalence of MSD’s is higher in labor intensive production units such
as furniture and heavy machinery.5

Economic and Humanistic Burden of MSD's
MSD’s have substantial economic and humanistic impact on the US health care
system. The annual direct and indirect costs for the treatment of MSD’s is approximately
$849 billion, which is around 7.7% of the US Gross Domestic Product (GDP). 3 Over the
last decade, there has been two percentage points increase in the population that needs
medical care for problems related to MSD’s. This has resulted in a 41% increase in
direct medical costs associated with MSD's. 6
The direct cost of treatment of MSD’s in 2002-04 was $510 billion (~ 4.6% of US
GDP).6 Almost 85% of the people affected by the MSD's reported at least one
ambulatory visit to physician’s office. In 2002-2004, ambulatory physician visits due to
2

MSD's were 507.9 million (52%) compared to 425.5 million (40%) in1996-1998.6 Due
to an increase in the number of MSD’s-related visits over the same period, a 69%
increase in the total non-physician ambulatory visits at a cost of $135.3 million was
incurred.6 Prescription drug utilization is also significant in this population. The mean
prescriptions filled per person increased from 13.1 in 1996-1998 to 18.6 in 2002-2004
resulting in a financial burden of $1.6 billion in 2002-2004.6
The indirect costs of MSD’s in the age group of 18-64 years were $339 billion (~
3.1% of the US GDP). Some of the major factors that contribute to these costs include
loss in wages due to presenteeism (not functioning to 100% of the work ability), and
absenteeism (absent from work due to an illness). 6 Additionally, individuals with MSD’s
have reportedly decreased the numbers of hours they work, some have changed jobs that
require less physical activity, while others have completely left working, thereby adding
to the loss in productivity.7
In addition to the economic impact, MSD’s have a tremendous effect on
individual’s quality of life (QoL).3 Compared to gastrointestinal conditions, chronic
respiratory diseases, and cardiovascular conditions, individuals with MSD's report poorer
QoL, especially for bodily pain and physical function.8 Musculoskeletal disorders are
also a major cause of pain in the elderly population and are responsible for functional
impairment which restricts mobility and self-care tasks.9 MSD’s are one of the most
common cause of disability in the US. MSD's cause many long-term physical disabilities
whose impact sometimes leads to major changes in the life of the people suffering from
these disorders. The impact of MSD's on the health-related quality of life (HRQoL) of
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individuals due to its impact on pain and reduced physical function is also well
documented.9

Pathology, Epidemiology and Management of Major Disorders under MSD’s
Gout
Gout is a heterogeneous disease characterized by deposition of monosodium urate
crystals in the joints and surrounding tissues resulting in severe pain and erythema. 10
Depending on the severity of the disorder, gout can be classified into acute and chronic
gout. The symptomatic classification of gout is as follows11: asymptomatic
hyperuricemia, acute gouty arthritis, intercritical gout, and chronic tophaceous gout.
The prevalence of gout in the US is higher than many countries and the rates
range from 0.47% to 0.52%.11 Elderly individuals, those with transplantation (allograft)
and renal insufficiency are at an increased risk of developing gout. 12 The most common
risk factor associated with gout includes hyperuricemia which is generally triggered by
the consumption of alcohol and diet rich in purine, drugs such as thiazide diuretics, loop
diuretics, and cyclosporine also play a role in potentiating the development of
hyperuricemia.12
The monitoring of renal uric acid excretion is important for the systematic
management of gout. However, the presence of co-morbidities, especially in the acute
stages of gout complicates the disease management. The following drugs are commonly
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used in the treatment of gout: colchicine, NSAIDs (Ketoprofin and Ibuprofen),
corticosteroids, anakinra, uric acid lowering drugs (allopurinol, xanthine oxidase
inhibitor), febuxostat (novel drug with more potency), probencid, and pegylated uricase. 10

Ankylosing Spondylitis
Ankylosing Spondylitis (AS) is a chronic disabling arthritic condition
characterized by severe inflammatory chronic back pain. 13 The occurrence of AS is
strongly associated with the expression of HLA B27genotype and is also triggered by
microbial infections. As the disease progresses, the joint pain worsens, and the
inflammation spreads to eyes, hips, knees, lungs, entire spinal assembly, shoulders,
tendons and various ligaments attached to bones. 14 The incidence of AS is estimated at
0.8 % in adults aged 25 to 49 years.14 Males are more susceptible to AS compared to
females and this disorder also affects young adults between the ages of 20 and 30 years. 14
The goal of AS management is to reduce the intensity of inflammation, pain and
stiffness due to the disease.14 The commonly used drugs are NSAIDS, analgesics
(paracetamol and opioid drugs), disease modifying anti-rheumatic drugs (methotrexate
and sulfasalazine)15 and tumor-necrosis-factor alpha (TNF-α) blockers (etanercept,
infliximab, adalimubab, and golimubab). 16

5

Osteoarthritis
Osteoarthritis (OA) is a degenerative joint disorder that mainly affects the
cartilage cells. It is considered an acquired degenerative process due to its genetic
predisposition. Around, 70- 90% of the geriatric population (75 years and above) have at
least one joint affected with OA and this condition is considered as the second most
common form of disability among women and men. This condition can be managed and
treated by family physicians but in severe cases, surgery is recommended. The OA of
knee and hip are very common with a prevalence of 6% and 3%, respectively in US
adults.17
A variety of factors such as heredity, age, deposition of urate crystals in the joints,
occupational markers, high bone mineral density, peripheral neuropathy, obesity and
trauma are probable risk factors of OA. Some factors such as severe athletic exercises
and sports involving torsional impact are also considered as probable risk factors of
OA.18
The management of OA includes pharmacotherapy, physiotherapy, novel genetic
engineering techniques and also patient education. The medications that are
recommended to relieve the pain are NSAIDs and analgesics. The alternative medicine
for OA includes glucosamine sulfate and chondroitin sulfate although their clinical
effectiveness is yet to be proven.19
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Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic, inflammatory, autoimmune disorder
which is characterized by severe inflammation in the joints along with swelling, stiffness,
damage of the cartilage and bone around the infected joint. There is no complete cure for
this disease, however, there are a number of disease modifying anti-rheumatic drugs,
NSAIDS, analgesics, steroids, physical exercises and patient education that are
recommended in the management of RA.20 RA results in permanent damage to the
affected part or deformity or immobilization accompanied by symptoms like low grade
fever, fatigue, anemia, pericarditis, myocarditis or pulmonary fibrosis. This disorder
affects the individual’s life style and severely compromises their QoL. 21 RA affects
around 1.3 million people in the US with an increase in the disease incidence seen in
women over the last decade.21

Problem Statement
MSD’s are a major cause of morbidity and health care burden in the US and their
impact on clinicians, payers, patients, and the society as a whole is pervasive. In the US,
MSD’s were reported by 107 million adults in 2005 and were the leading cause of
disability accounting for more than one-half of all chronic conditions in individuals over
50 years of age. Given the high prevalence rates, these conditions have been consistently
included as leading health indicators in both Healthy People 2010 and 2020. 22 The
prevalence of MSD's have been shown to increase markedly with age, and are affected by
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lifestyle factors, such as obesity and lack of physical activity. With a projected increase
in the aging population over the next two decades, coupled with an increasing sedentary
lifestyle, there is a strong possibility for a dramatic increase in the burden of MSD’s on
the society.23 The burden of MSD’s in terms of resource utilization and costs to the
society would thus be staggering. Current estimates show that MSD’s present a multibillion-dollar-a-year burden on the society.23 The per capita medical care expenditures of
persons with musculoskeletal conditions in 1996 averaged $3,578, amounting to a
national total expense of $193 billion (~2.5% of US GDP). 24 By 2006, the medical
expenditures for MSD's had increased to $950 billion (7.4% of GDP) and this is further
expected to increase given the expected growth in the aging population. 6
In MSD's, the major direct cost components include hospitalizations, ambulatory
care, and prescription drugs. People with MSD’s have 50% higher health care
expenditures compared to non-MSD’s ($3,578 against $ 2,313). Out of the total health
care cost, hospitalization costs accounts for 37% of the cost . 25 Additionally, indirect
costs, primarily in the form of lost wages associated with MSD's, contribute substantially
to the health care burden with an estimated cost of $373.1 billion in 2006 (~2.9% of US
GDP).6
Prescription drug cost is another major component of the overall direct medical
cost, along with the physician and other service provider costs in MSD's. In the last
decade, there has been a paradigm shift in the treatment of MSD’s, especially with the
introduction of biologic therapies in RA and AS. Biologics are reported to have excellent
therapeutic efficacy, however, the treatment cost has increased significantly as these
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classes of drugs are very expensive. 26 Previous estimates of the burden of MSDs on the
society have not included the cost impact of these biologics on the total health care costs.
Thus, there is a gap in the literature on the new treatment cost estimates and the type of
health care resources that are utilized in MSD’s. Moreover, it is important to assess the
cost of treatment of MSD's, especially under different service categories like inpatient,
outpatient, and prescription drug services. It would also be of great interest to different
decision makers such as payers and clinicians to know the incremental costs of MSD's
compared to the other disease conditions. Incremental cost calculations can help
understand the contribution of different service categories to the overall costs and
therefore, facilitate decisions pertaining to efficient resource allocation.
The costs assessment needs to focus on important demographic factors such as
gender, race, age, and geographic region to better understand the disparity in terms of
prevalence and national estimates among individuals with MSD’s. Specifically, studies
have shown that women and elderly are majorly affected by MSD’s. Thus, assessing the
treatment cost of MSD's based on demographic profiles would further help in
determining the predictors of resource utilization and identifying US regions where there
is a high prevalence and resource utilization. The study estimates can serve as a guide for
policy makers in the formulation of health care policies on screening, treatment
guidelines, and identification of high-risk population for MSD's.

9

Conceptual Framework
The objective of this study is to develop a national assessment of the incremental
resource utilization in individuals with MSD’s compared to those without MSD’s, using a
retrospective analysis of 2007 Medical Expenditure Panel Survey (MEPS) data.
Incremental cost analysis is a decision-making technique used to determine the true cost
difference between alternatives. In addition to calculating the incremental costs, the
study has two more objectives. First, to focus on the different health care service
categories that contribute to the overall health care expenditures in individuals with
MSD’s and non-MSD’s and second, to evaluate the disparity in demographic variables
such as age, gender, race, and geographic location on different health care service
categories.
The study will use 2007 MEPS data for all the analysis. MEPS is a third in the
series of nationally representative surveys of medical care use and expenditure sponsored
by the Agency for the Health Care Policy and Research (AHCPR). 27 MEPS database
provides national information on the types of health services used in the US, and how
frequently the health services are used.
MEPS database comprises of three components. These include:
1) Household component (HC): Provides detailed information on the demographic
characteristics, health status, health insurance, employment, and medical care use and
expenses of the individuals.
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2) Medical Provider Component (MPC): Provides additional information on specific
International Classification of Diseases - 9 ( ICD-9) codes, Current Procedural
Terminology (CPT) codes and Diagnosis-Related Group (DRG) codes used by the
physicians and hospitals.
3) Insurance Component (IC): Provides data on the number and types of private health
insurance plans offered, benefits associated with these plans, premiums, contributions by
employers and employees, eligibility requirements, and employer characteristics.
The study will use the HC and MPC of the 2007 MEPS database. The study will
identify the individuals diagnosed with MSD's and those without MSD’s, and categorize
them into two cohorts based on the ICD-9 codes. Overall disease burden, incremental
costs, health care expenditures including different service categories and demographic
disparities in health care expenditures will be estimated in the two cohorts.
Hypothesis
The overall hypothesis is that resource utilization in individuals with MSD’s will
be higher than the non-MSD cohort.

Study Objectives
The specific study objectives include:
Objective 1: To identify the characteristics of the total population surveyed in 2007
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MEPS data.
Objective 2: To identify the demographic characteristics of individuals diagnosed with
MSD's and non-MSD in 2007 MEPS data.
Objective 3: To estimate the mean expenditures for total health care expenditures, total
office-based expenditures, total outpatient expenditures, total inpatient expenditures, total
emergency room expenditures, total office-based chiropractor expenditures, and total
prescription expenditures in individuals with MSD's and non-MSD.
Objective 4: To identify the predictors for total health expenditures, total office-based
expenditures, total outpatient expenditures, total inpatient expenditures, total emergency
room expenditures, total office-based chiropractor expenditures, and total prescription
expenditures in individuals with MSD's and non-MSD.
Objective 5: To calculate a national estimate for the total incremental health care
expenditures of MSD's compared to non-MSD.

Significance of the Study
The overall goal of the study is to provide prevalence and cost estimates for
MSD's using 2007 MEPS data. The study aims at updating old cost estimates from the
1990s since there has been a significant change in the management of MSD's. This study
can be instrumental in public health policy debates as it highlights the magnitude of the
impact of MSD's on our society. The calculation of the cost estimates for different
12

service categories are useful in understanding the value of new technologies that are
introduced in the market. Once the true cost impact of the disease is known, policy
makers can then estimate the resources that could potentially be saved or gained if the
disease is managed at an early stage. It would also be useful to understand the possible
cost offsets that can accrue due to the implementation of preventive programs such as
screenings or testing. Based on past research, preventive programs have been shown to
be cost effective and result in efficient use of existing health care technology. Thus, the
overall costs assessment can help policy makers decide the right course of action in terms
of resource allocations and prevention policies.
Understanding the socio-demographic characteristics of individuals with MSD's
will aid in indentifying the population at-risk by studying the predictors and by further
studying the sub-categories which are significant for the specific health care service
categories. Based on the study results, emphasis can be placed on interventional
strategies that can target these populations with a goal of reducing the disease prevalence.
These interventions are also helpful in improving the QoL of the individuals and the
significant resource utilization associated with MSD's. Evidence from similar
intervention strategies for diabetes and hypertension have shown that these strategies are
very effective in lowering the disease incidence and reducing cost of disease
management.28 This study includes a number of MSD’s such as invertible disc disorder,
curvature of spine that are less prevalent in the population but incur significant resource
utilizations. In the past, studies have mainly focused on major MSD conditions such as
RA, OA, AS, and gout.
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The study results can be used by different stake holders in developing new and
improved disease management strategies. From a clinician’s perspective, this study will
provide them with information about the target population and the need for adhering to
appropriate treatment guidelines. This study will help managed care organizations to
better understand the cost burden of MSD's and assist them in structuring effective
guidelines to provide low cost and better care to individuals with MSD’s. The study will
further provide significant information to the policy makers for setting priorities in
resource allocation, taking into account the huge economic impact of these conditions.
The next chapter will discuss the prevalence and costs studies that have been
conducted in MSD’s.
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CHAPTER TWO
LITERATURE REVIEW
This chapter provides an in-depth review of the literature for the following: (i)
MSD's-related prevalence, (ii) Burden of MSD's on the US health care system.

Search Strategy
Following the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines, a systematic literature search was conducted among
peer-reviewed journals from January 1990 to January 2012 in electronic databases such
as Pubmed (Figure 1).29 The search was limited to studies in English language.
The search strategy included the following search terms or their combinations:
musculoskeletal disorders, rheumatic condition, rheumatoid arthritis, osteoarthritis, joint
pain, cost, disease burden, prevalence, epidemiology, predictors, biologics, service
categories, inpatient, outpatient, prescription drugs, and emergency room.

Inclusion/Exclusion Criteria
Articles were included in the final review if they estimated the prevalence of
MSD’s or if they assessed the cost impact of MSD's. Randomized clinical trials, drugspecific cost studies, pharmacoeconomic studies for MSD's treatments, costs studies
conducted outside of the US, and review articles were excluded from the review.
15

Figure 1.PRISMA diagram elaborates the step wise selection of studies for the literature

Identification

search.

Records identified through
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(n = 130)
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(n =0 )

Screening

Records after duplicates removed
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Included
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studies = 25
Full-text articles assessed
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(n = 10)

Studies included in final
review
(n = 10)
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Non-English studies = 17

The 10 articles included in the review were categorized as follows:


Prevalence of MSD's.



Burden of MSD's on the US health care system.

Prevalence of MSD's
There are only four studies that have estimated the prevalence of MSD’s in the
US population. The Bone and Joint Organization used the 2008 National Health
Interview Survey (NHIS) to estimate the prevalence of MSD's and reported
approximately, 110.34 million adults with a musculoskeletal condition. 6 Jacobs and
colleagues (2008) reported a total of 107.7 million adults suffering from musculoskeletal
conditions with one in two adults suffering from MSD's in 2005.30 Older estimates
indicate that the prevalence of MSD’s in the US has increased at an alarming rate. Yelin
and colleagues (2001) reported a prevalence rate of 53.93 million adults, which was
approximately 20.1% of the US population in 1996. 24 Another study by Lawrence and
colleagues (1998) used the 1990 National Health and Nutrition Examination Survey
(NHANES) data to estimate the prevalence of MSD’s and then extrapolated the results to
the year 2020. Approximately, 37.9 million (15%) individuals in 1990 had some form of
arthritis or rheumatic condition and MSD cases were predicted to increase to 59.4 million
(18.2%) by 2020.31
Yelin and colleagues (2007) expanded the definition of MSD’s to include other
rheumatic conditions such as rheumatic fever, other peripheral vascular disease, and
polyarteritis nodosa and allied conditions and labeled the group as arthritis and other
17

rheumatic conditions (AORC). The authors estimated the prevalence of AORC between
1997 and 2003 using MEPS database. The prevalence of AORC in 1997 was 36.799
million adults (18.7% of the US population), and increased to 46.114 million in 2003
(21.5% of the US population).32 Some prevalence data have also been reported for
specific MSD conditions such as RA, OA, AS, and gout. Simon and colleagues (2012)
reported the prevalence rates of RA over three consecutive years: 0.40% in 2004, 0.44%
in 2005, and 0.43% in 2006. Helmick and colleagues (2008) used 2005 National Health
Interview Survey (NHIS) data to estimate the prevalence of OA, AS, and gout. Nearly 27
million adults had clinically proven osteoarthritis (up from 21 million in 1995). The
prevalence rate of AS was 30 - 900 per 100,000 and gout was self-reported by 3 million
adults (up from 2.1 million in 1995). 33
Prevalence estimates from the literature suggests that the rate has nearly doubled
in the last two decades. The prevalence of MSD's in the US shows a rising trajectory
especially due to the dramatic growth in numbers and proportions of the elderly coupled
with increased life expectancies.

Burden of MSD's on the US Health Care System
Three studies have reported economic burden of MSD's on the US health care
system. Jacobs (2008) estimated the total cost for MSD’s treatments at $849 billion with
$510 billion in direct costs and $339 billion in indirect costs. Just like the prevalence
data, older estimates are considerably lower than the newer estimates.30 Yelin and
colleagues (2001) utilized the 1996 MEPS data to estimate the national expense and
individual’s annual average medical care expense for MSD’s. The national expense for
18

MSD’s was estimated at $193 billion with an individual’s annual average expense at
$3,578.24 In another study, Yelin and colleagues (2004) expanded the definition of
MSD’s by including rheumatic conditions and used this group to estimate the earning
losses of individuals with AORC. Estimates from the 1997 MEPS data indicated a total
of 38.4 million individuals with AORC, with an individual’s mean total medical
expenditure at $4,865 and a national annual burden of $186.9 billion. 32
Yelin and colleagues conducted two studies that estimated the predictors of
resource utilization. The first study utilized the 1996 MEPS data to study the predictors
of MSD’s while the second study utilized the 2003 MEPS data to study the predictors
AORC. For both MSD’s and AORC, inpatient cost was the biggest contributor to the
total resource utilization. In MSD's, inpatient cost was 37% of the total cost compared to
32% for AORC. After inpatient costs, outpatient costs were the next category that
contributed most to the resource utilization. For MSD's, the outpatient costs contributed
23% to the total cost while for AORC, it was 32%. Since the additional conditions
included under AORC compared to MSD’s require more outpatient treatment, there is a
trend for more expenditure on an outpatient basis for AORC compared to MSD’s.
Similarly, MSD’s require more hospitalizations and therefore, the trend for MSD’s was
higher expenditures in inpatient setting compared to AORC. Prescription drug costs were
also a major contributor to the overall cost for MSD’s (16%) and AORC (23%). 24, 32
Predictors of resource utilization for specific musculoskeletal conditions have also
been reported in the literature. Lurie and colleagues (2008) estimated the out-of-pocket
costs in individuals with RA from 1998 to 2004 using MEPS data. The total out-ofpocket expenditures among individuals with RA increased by 52.5%, primarily due to a
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72% increase in the median out-of-pocket expenditures for RA prescription drugs from
1998 to 2004.34 Gabriel and colleagues (1997) estimated the direct medical costs
associated with OA and RA and compared the costs to a control group which included
individuals without arthritis. The use of prescription medications was higher for RA
(96.3%) and OA (96%) compared to the control group (83%). 35
Studies have calculated the incremental costs of MSD’s compared non-MSD.
Individuals with MSD’s had 50% higher care expenditures ($3,578) compared to the nonMSD's cohort ($2,313) with a national incremental cost of $193 billion. Another study
calculated the mean incremental medical care expenditures attributable to AORC
reported an incremental cost of $1,752, with a national burden of $80.8 billion.24, 32
This review highlights the paucity of recent estimates of MSD’s prevalence rates,
total economic burden, and the predictors of resource utilization. The goal of the current
study is to provide newer estimates based on the 2007 MEPS data.
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CHAPTER THREE
METHODOLOGY

This chapter describes data source, data extraction, independent and dependent
variables, and the statistical analyses used in the study.

Data Source
The study utilized 2007 Medical Expenditure Panel Survey (MEPS) data for all
the analyses. The MEPS data is sponsored by the Agency for Health Care Policy and
Research (AHCPR) and is administered annually since 1996. The MEPS data measures
the frequency of the health care services utilized by US civilian non-institutionalized
population and provides national estimates of the medical use and total expenditures of
health care resources. In addition to the treatment cost, the database also provides
demographics (e.g., age, gender, and race), and insurance information (e.g., public,
private, and uninsured) of the participants.
The MEPS data is collected through a series of five rounds of interviews that span
a period of 2½ years. The interviews are conducted on a nationally representative sample
of households using an overlapping panel design. Since the current study is conducted
using a cross-sectional 2007 MEPS data, analytical adjustments were made using sample
weights to accommodate the panel design. In complex survey designs, such as that used
in MEPS, sample data must be multiplied by the appropriate sample weights to obtain
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unbiased estimates for the US civilian non-institutionalized population. Sample weights
provided within the MEPS data were used to estimate the national and regional
expenditures of different health care service categories. The sample weights also account
for equal representation of certain sections of the society which have been under
represented in the surveyed population. These weights are also needed to correct for
imperfections in the sample that might lead to bias and other departures between the
sample and the reference population. Such imperfections include the selection of units
with unequal probabilities, non-coverage of the population, and non-response.
The MEPS data includes the following three components:
1) Household Component: The Household Component (HC) is a national representative
survey of the non-institutionalized civilian population. The structure and design of HC is
very descriptive and provides detailed information on the population’s demographic
characteristics, health status, employment status, and their access to health care services.
This component helps in understanding the complex research objectives such as the use
of health services and expenditures, changes in provision of health care in relation to
social and demographic factors and needs of a specific population group such as the
elderly and children.
2) Medical Provider Component: The Medical Provider Component (MPC) is a survey of
the medical providers, facilities, and pharmacies that provide health care services to
individuals and families included in the survey. This component provides detailed
information on the expenditure and payment sources of the respondents.
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3) Insurance Component: The Insurance Component (IC) is designed to estimate the
national and state-level cost of employer-sponsored coverage's. These estimates provide
information on the amount spent, type of insurance, and cost of the job-related health
insurance.
MEPS data provides information that can be useful in conducting a variety of
research projects. Some examples include:
1) Research on health care expenditure and their sources of payments: MEPS data
provides in-depth information on individual’s total and out-of-pocket health care
expenditures. The amount of health care services such as outpatient facility, inpatient,
prescription drug, emergency room, and their sources of payment like Medicare,
Medicaid, or private insurance can also be estimated.
2) Research on vulnerable population groups: The disparity in the utilization of health
care resources and access to care among different population groups have been of
immense concern to policymakers. MEPS data can provide valuable information to
policy makers regarding the size and composition of a particular subset of population that
are disadvantaged in terms of access and use of the various health care resources.
3) Research on private and public health insurance: MEPS data provides information on
the health insurance status of the individuals and their family members. Additional
insurance information such as premiums, employer and employee contributions, types of
plans, and details on the scope and copayment provisions is available. The data is useful
in estimating the health insurance in general, the interplay of specific insurance plans,
and the use of health care resources.
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The 2007 MEPS data contains variables and frequency distributions of 30,964
individuals who participated in the HC.

Study Population
The study population was divided into two cohorts based on the presence or
absence of MSD's. Individuals with a primary diagnosis of conditions included under
MSD’s were selected. Table 1 lists all the disease conditions that are included under
MSD’s. The individuals categorized in the MSD cohort had ICD-9-CM codes of 278.00
and 710.00-738.00. Individuals without the MSD’s codes were categorized into the nonMSD cohort.

Data Extraction

The 2007 consolidated full year file and medical conditions file were downloaded
from the MEPS website (http://meps.ahrq.gov). The files were unzipped and
decompressed to extract the data in ASCII format. The ASCII files were then converted
to Predictive Analytical Software (PASW) version 18.0 with the help of SPSS load
programs which were also downloaded from the MEPS website. The consolidated full
year file and medical conditions file were then merged using the ICD-9-CM codes for
MSD's (274.00 and 710.00-738.00).

24

Table 1: Disease conditions categorized under MSD's

ICD-9-CM

DISEASE CONDITION

274.00

Gout

710.00

Systemic lupus erythematosus

711.00

Arthropathy associated with infections

712.00

Crystal arthropathies

713.00

Arthropathy, endocrine disorders

714.00
715.00
716.00

Rheumatoid arthritis
Osteoarthrosis
Other & unspecified arthropathies

717.00

Internal derangement of knee

718.00

Other derangement of joint

719.00

Other & unspecified disorders of joint

720.00

Ankylosing spondylitis

721.00

Spondylosis & allied disorders

722.00

Intervertebral disc disorders

723.00

Other disorders of cervical region

724.00

Other & unspecified disorders of back

725.00

Polymyalgia rheumatica

726.00

Peripheral enthesopathies & allied syndromes

727.00

Other disorders of synovium, tendon, & bursa

728.00

Disorders of muscle, ligament, & fascia

729.00
730.00
731.00

Other disorders of soft tissues
Osteomyelitis, periostitis, & other infections
Osteitis deformans & osteopathies

732.00

Osteochondropathies

733.00

Other disorders of bone & cartilage

734.00

Flat foot

735.00

Acquired deformities of toe

736.00

Other acquired deformities of limbs

737.00

Curvature of spine

738.00

Other acquired musculoskeletal deformity

________________________________________________________________________
ICD-9 CM: The International Classification of Diseases Ninth Revision Clinical Modification
Based on the recommendation of the National Arthritis Workshop (1996)
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Independent Variables
Presence of MSD's
The main variable was the presence of MSD's. In the MEPS data, the medical condition
of the respondents was provided as ICD9CODX which was recoded into a new variable
“MSD” and categorized as “Yes” and “No".
Census Region
This variable provides geographic information of the survey respondents. In the MEPS
dataset, geographic region information was provided as REGION07. It was recoded into
a new variable "Census Region". The patient’s geographic region was categorized as:
Northeast, Midwest, South, and West.
Age
This variable provides information on the age of a respondent and was reported as a
continuous variable. In the MEPS dataset, age information was provided as AGE07X.
This variable was recoded as "AGE IN YEARS", by dividing the sample into four
categories 0-18 years, 19-40 years, 41-64 years, and 65 years and above.
Race
This variable provides information on the race of a respondent. In the MEPS dataset,
race information was provided as RACEX. This variable was recoded as "RACE". In
MEPS, the variable race was categorized into White, Black, Asian, Pacific Islander,
Native American, and Mixed race.

26

Gender
This variable provides gender information of the survey respondents. In the MEPS
dataset, gender information was provided as "SEX". The gender variable was
categorized as male and female.
Education
This variable represented the education in years for the survey respondents. In MEPS,
education years information was provided as EDUCYR. This variable was recoded as
"EDUCATION YEARS". Education in years was originally recorded as a continuous
variable and was recoded as categorical variables with three categories: less than 12 years
of education, individuals with 12 years of education, and individuals with more than 12
years of education.
Marital Status
This variable provides information about the marital status of the survey respondents. In
MEPS, marital status information was provided as MARRY07X. This variable was
recoded as "MARITAL STATUS". This variable represents the marital status of an
individual and was categorized as Married, Separated, Never Married, and under the age
of 16 years.

Outcome Variables
Total Health Care Expenditures
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This variable provides the total health care expenses and is useful in estimating the
overall burden of MSD’s on the health care system.
Total Office-based Chiropractor's Expenditures
This variable provides the office-based chiropractor's expenses. This expense is a part of
the office-based expense which the individuals with MSD's incur.
Total Inpatient Facility Expenditures
This variable provides the inpatient facility expenses including procedures and drugs for
the MSD’s and the non-MSD population.
Total Outpatient Facility Expenditures
This variable provides the total outpatient facility expenses including physician and nonphysician care visit charges for MSD’s and non-MSD population.
Total Emergency Room Expenditures
This variable provides the total emergency room expenses for MSD’s and non-MSD
population.
Total Prescription Drug Expenditures
This variable provides the total cost of prescription drugs for MSD's and non-MSD
population.
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Data Analysis
Data was analyzed using Predictive Analytical Software (PASW) version 18.0.
As discussed earlier, national estimates from MEPS data was calculated by applying
sample weights.
For all the regression models, a p-value of 0.05 was selected a priori as the
significance level. For the analysis, a simple linear regression model was used:
Y = C + B1X1 + B2X2 …..+ E
Y = Dependent variable, C= Intercept, B1, B2 = Beta coefficients, X1, X2 =
Independent variables, E = Error component
The dependent variable in the regression model was the total expenditures for
different service categories while the independent variable was the presence of MSD's.
Age, gender, race, marital status, census region and education years were included as
independent variables in the analysis. The model was based on the study by Balu and
colleagues that estimated the incremental expenditure of hypertension. 36
Expenditure = Intercept + B1Presence of MSD + B2Age + B3Gender + B4Race +
B5Marital Status + B6Census region + B7Education years + E

Assumptions for Regression Model
The following assumptions were tested before the regression analyses were
conducted and no serious violations of the assumptions were observed. Here the
independent variables (IVs) refer to age, gender, race, marital status, census region,
29

education years and the dependent variables (DVs) refer to the total health care
expenditures, total office-based chiropractor expenditures, total outpatient expenditures,
total inpatient expenditures, total emergency room expenditures and total prescription
expenditures.
Linearity of the relationship between the IV and the DV
If the relationship between IV and DV is not linear; the regression analysis results
most likely under-estimate the true relationship. We conducted scatter plots of both IV
and DV and found the relationship to be linear. In order to quantify the strength of the
linear relationship, a numerical measure of association between the two variables was
estimated using the correlation coefficient. A value between -1 and 1 indicated the
strength of the association of the observed data for the two variables. Our results
indicated that there was a strong linear relationship between the IVs and DVs since the
coefficient correlation values were greater than 0.4.
Independence of errors to check for no serial correlation
Independence of the variables in a reported data is based on the assumption that
all the variables recorded at the time of collection are independent. In order to determine
the independence of variables, two tests were conducted. Tolerance is the proportion of a
variable's variance that is not accounted for by the other IVs in the equation. A tolerance
value close to 1 indicates very little multicollinearity, whereas a value close to 0 suggests
that multicollinearity may be a threat. For this study, all the tolerance estimates were
around 1 indicating very little or no multicollinearity. The second test to check for
independence was the Variance Inflation Factor (VIF) which is the reciprocal of tolerance
and quantifies the severity of multicollinearity in a regression analysis. The acceptable
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range of VIF is a score less than 10. For this study, the VIF scores for all the IVs were
less than 10, further indicating very little or no multicollinearity.
Homoscedasticity (assumption of constant variance)
The assumption of homoscedasticity is that the residuals are approximately equal
for all predicted DVs scores. Homoscedasticity was tested by conducting scatter plots
between each IV and DV. In the residual plots, the clusters of points were approximately
the same width indicating that DVs exhibited similar amounts of variance across the
range of values for the IVs.
Normality of the error distribution
The sample size in the 2007 MEPS data was 94,246. According to Central Limit
Theorem, a sample distribution is approximately normal if the sample size is greater than
30. So the data was considered approximately normal. We still tested this assumption
using two tests. Kurtosis is a measure of the shape of the probability distribution of a
real-valued random variable. For a distribution to be normal, kurtosis scores should be
within the range of -1 to +1. Study results were in the acceptable range of -1 to +1.
Skewness was also conducted to check for normality. Skewness is a measure of the
asymmetry of the probability distribution of a real-valued random variable. The
acceptable range for skewness test is -1 to +1 for a normal distribution. The study results
were also in the acceptable range. Both these tests confirmed the normality of the data.
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Regression Analysis
For the regression analysis “Enter” Method was used. "Enter" method enters all
variables into the regression model at the same time. This is the default method to
conduct a regression analysis in SPSS. Other hierarchical methods that are used in
regression models include “Backward”, “Forward”, and “Stepwise”. The hierarchical
methods are used when specified order should reflect some theoretical consideration or
previous findings. “Enter” method was selected for the analysis because there was no
reason to believe that one variable is likely to be more important than another.
The following analyses were conducted based on the specific study objectives.
Objective 1: To identify the characteristics of the total population surveyed in 2007
MEPS data.
The frequencies for all the individuals in the database were assessed. The mean
age was reported and the frequencies for age, gender, race, marital status, education
years, and census region were analyzed. Sample survey weights were used to estimate
the weighted and non-weighted prevalence of the MSD's.
Objective 2: To identify the demographic characteristics of individuals diagnosed with
MSD's and non-MSD in 2007 MEPS data.
The frequencies for age, gender, race, educational years, marital status, and
census region for the individuals with MSD’s was reported
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In objectives 3, 4, and 5, the following regression model will be used for the estimation
of costs.
Y= Intercept + B1X1 + B2 X2 + B3 X3 + B4 X4 + B5 X5 + B6 X6 + B7 X7 + E
where B1-B7 = Beta Coefficients; E = Error term; Dependent Variable = Expenditures;
Independent Variables = Presence of MSD, Age, Gender, Race, Marital Status, Census
Region, Education years.
Expenditure = Intercept + B1Presence of MSD + B2Age + B3Gender + B4Race +
B5Marital Status + B6Census Region + B7Education years + E
In the regression model, intercept is where the regression line strikes the Y axis
when the independent variable has a value of 0. B1 is the slope of the IV (e.g., presence of
MSD’s). Similarly B2, B3, B4, B5, B6, B7 are the slopes of other independent variables age,
gender, race, marital status, census region, and education years, respectively. E is the
error component in the estimation of the total cost. The predicted value is calculated as
follows:
Predicted variable (dependent variable) = slope * independent variable + intercept
Objective 3: To estimate the mean expenditures for total health care expenditures, total
office-based chiropractor's expenditures, total outpatient expenditures, total inpatient
expenditures, total emergency room expenditures and total prescription expenditures in
individuals with MSD's and non-MSD.
A separate dataset was created to calculate the mean expenditures in each service
category for individuals with a MSD diagnosis. Descriptive analysis was conducted and
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a linear regression model was utilized to estimate the mean total health care expenditures,
mean total office-based chiropractor expenditures, mean total outpatient expenditures,
mean total inpatient expenditures, mean total emergency room expenditures and mean
total prescription expenditures. Certain independent variables were recoded as dummy
variables to examine any possible effect of the categorical variable on the DV. The
variables that were recoded were age, race, marital status, and education years.
The regression model used in the analysis was:
Expenditure = Intercept + B1Presence of MSD + B2Age + B3Gender + B4Race +
B5Marital Status + B6Census Region + B7Education years + E
Objective 4: To identify the predictors for total health expenditures, total office-based
chiropractor expenditures, total outpatient expenditures, total inpatient expenditures,
total emergency room expenditures and total prescription expenditures in individuals
with MSD's.
To identify the predictors of expenditures in each service category, a separate
dataset was created that contained individuals with a MSD diagnosis alone. A linear
regression model was utilized to estimate the mean total health care expenditures, mean
total office-based chiropractor expenditures, mean total outpatient expenditures, mean
total inpatient expenditures, mean total emergency room expenditures and mean total
prescription drug expenditures. The model used was
Expenditure = Intercept + B1Presence of MSD + B2Age + B3Gender + B4Race +
B5Marital Status + B6Census Region + B7Education years + E
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Objective 5: To calculate a national estimate for the total incremental health care
expenditures of MSD's compared to non-MSD.
To calculate a national estimate for the incremental health care expenditures for
treating MSD's, mean cost of individuals with non-MSD diagnosis was conducted. A
separate dataset with only individuals with non-MSD conditions were included. A linear
regression model was run, using the “Enter” method. Cost of treatment under separate
service category for the mean total health care expenditures, mean total office-based
chiropractor expenditures, mean total outpatient expenditures, mean total inpatient
expenditures, mean total emergency room expenditures and mean total prescription
expenditures were calculated. The incremental difference between MSD's and non-MSD
was calculated. The mean incremental difference was then multiplied by the prevalence
of MSD's cases for the year 2007.
National estimate for the total incremental health care expenditures = National
Prevalence × estimated incremental expenditures

Adjustment of Total and Incremental Costs to 2011 Values:
The costs from the 2007 MEPS data was inflated to year 2011 value by using the
standardized inflation rates published by the Bureau of Labor Statistics (BLS).37 This
adjustment presents the economic burden of MSD’s on the society in today’s value.
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CHAPTER FOUR
RESULTS

In this chapter, results for each of the study objectives are presented.
The full year consolidated data file and the medical component file of the 2007
MEPS data was utilized. From this dataset, patients were categorized as MSD’s and nonMSD. Based on the National Arthritis Workshop recommendations, patients with ICD-9CM codes of 274.00 and 710.00 to 738.00 as their primary diagnosis were categorized as
having MSD’s and the rest were categorized as non-MSD.38 The 2007 MEPS database
surveyed a total of 94,246 individuals. After the sample weights were applied, the
national data represented 301,309,149 individuals.

Objective 1: To identify the characteristics of the total population surveyed in 2007
MEPS data.
A descriptive analysis was conducted to determine the frequencies (weighted and
unweighted) of age, gender, race, education years, geographic region, and census region
of the population surveyed in 2007 MEPS data (Refer Table 2). In the survey population
(n=94,246), a majority of the respondents were under 18 years of age (30.8%) followed
by 41 to 65 years (29.9%). The mean age of the respondents was 34.53±22.73 years
(Mean±SD). There were 52.1% females and the survey population was predominantly
white (74.5%), married (38.9%), with >12 years of education (44.9%), and from the
Southern region of the US (38.0%).
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Table 2: Characteristics of the total population surveyed in 2007 MEPS data.

Variable

level

Unweighted data

Weighted data

N (%)

N (%)

Age (years) (Mean±SD)

34.53±22.73

36.51±22.60

Age (years)

0 - 18

9,460 (30.8)

92,803,217 (31.0)

19 - 40

8,803 (28.6)

86,174,416 (28.3)

41-65

9,206 (29.9)

90,091,435 (30.2)

> 66

3,278 (10.7)

32,240,078 (10.5)

Male

14, 817 (47.9)

144,327,082 (47.9)

Female

16, 417 (52.1)

156,982,066 (52.1)

White

23,705 (74.5)

224,475,316 (74.6)

Black

5,404 (17.5)

52,729,101 (17.5)

Native Hawaiian

387 (1.2)

3,615,709 (1.2)

Asian

1,442 (4.7)

14,161,530 (4.6)

Mixed race

656 (2.1)

6,327,492 (2.1)

Northeast

4,517 (14.7)

44,292,444 (14.7)

Midwest

6,224 (20.2)

60,864,448 (21.1)

South

11,699 (38.0)

114,497,476 (37.0)

West

8,307 (27.0)

81,353,470 (27.2)

Married

12, 044 (38.9)

117,209,259 (38.0)

Separated

4,417 (14.3)

43,087,208 (15.0)

Never Married

6,600 (21.3)

64,178,848 (21.5)

age

7,893 (25.5)

76,833,833 (25.5)

<12 years

4,656 (22.4)

67,493,249 (22.5)

12 years

6, 812 (32.7)

98,528,091 (32.5)

> 12 years

9,336 (44.9)

135,287,807 (45.0)

Gender
Race/ Ethnicity

American Islander &

Census Region

Marital Status

Under 16 years of
Education Years

N = Number of individuals
SD = Standard deviation
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Objective 2: To identify the demographic characteristics of individuals diagnosed with
MSD's and non-MSD in the 2007 MEPS data.
Among the surveyed individuals (n= 94, 246), 10, 696 (11.3%) were categorized
as MSD's and the rest were categorized as non-MSD (n= 83,550; 88.7%). The weighted
national population of MSD’s and non-MSD were 33,075,541 (11.3%) and 268,233,608
(88.7%), respectively.
The mean ages for individuals with MSD’s and non-MSD were 34.63±22.99
years and 34.51±22.70 years, respectively. In the MSD’s and non-MSD cohort, a
majority of the individuals were under 18 years of age (31.1%, 30.7%) followed by 41 to
65 years (30.0%, 29.9%). Females (52.1%, 52.2%), whites (75.1%, 74.4%), individuals
with >12 years of education (43.4%, 45.1%), and Southern region of the US (38.6%,
38.0%) were predominant among both the MSD's and non-MSD cohort.
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Table 3: Demographic characteristics of MSD’s and non-MSD in the 2007 MEPS data.
MSD
N (%)
34.63±22.99

Non-MSD
N (%)
34.51±22.70

P-value

Variable
Age (years) (Mean±SD)

Level

Age (years)

0-18
19-40
41-65
>66

1,071(31.1)
960 (27.9)
1,031(30.0)
379 (11.0)

8,389 (30.7)
8,175 (28.7)
8,175 (29.9)
2,899 (10.6)

0.778**

Gender

Male
Female

1,662 (47.9)
1,806 (52.1)

13,155 (47.8)
14,341 (52.2)

0.929**

Race/Ethnicity

White
Black
Native American
& Hawaiian
Islander
Asian
Multiple Races

2,605 (75.1)
596 (17.2)

20,470 (74.4)
4,808 (17.5)

0.920**

41 (1.1)
157 (4.5)
69 (1.9)

346 (1.2)
985 (3.6)
587 (2.1)

Census Region

Northeast
Midwest
South
West

483 (14.0)
703 (20.4)
1,328 (38.6)
927 (26.9)

4,034 (14.8)
5,521 (20.2)
10,371 (38.0)
7,380 (27.0)

0.681**

Marital Status

Married
Separated
Never Married
Under 16 years of
age

1,324 (38.2)
484 (14.0)
757 (21.8)
903 (26.0)

10,720 (39.0)
3,933 (14.3)
5,843 (21.3)
6,990 (25.4)

0.632**

Education Years

< 12 years
12 years
>12 years

538 (23.1)
779 (33.5)
1,011(43.4)

4,118 (22.3)
6,033 (32.6)
8,325 (45.1)

0.323**

0.782*

N= Number of individuals, SD = Standard deviation, *Independent t-test , ** Chi-square test, Significance at p<0.05
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Objective 3: To estimate the mean expenditures for total health care expenditures, total
office-based expenditures, total outpatient expenditures, total inpatient expenditures,
total emergency room expenditures, total office-based chiropractor expenditures, and
total prescription expenditures in individuals with MSD's and non-MSD.
In order to estimate the cost of treatment for different service categories, two
separate datasets were created. The first dataset contained individuals with a diagnosis of
MSD's. All the other individuals without the MSD diagnosis were included into the nonMSD dataset. A multiple linear regression was conducted to estimate the mean health
care expenditures for individuals with MSD's and non-MSD under different service
categories like total health care expenditures, office-based expenditures, outpatient
expenditures, inpatient expenditures, emergency room expenditures, office-based
chiropractor expenditures, and prescription expenditures. The regression model used for
the two cohorts was:
Expenditure = Intercept + B1Presence of MSD + B2Age + B3Gender + B4Race +
B5Marital Status + B6Census Region + B7Education years + E
where B1-B7 = Beta Coefficients
E = Error term
Dependent Variable = Expenditure
Independent Variables = Presence of MSD, Age, Gender, Race, Marital Status, Census
Region, Education years
The mean total health care expenditures for the MSD's cohort were $91,121.41
compared to $90,234.91 for the non-MSD cohort (p< 0.05). The non-zero confidence
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interval suggested that there was a significant difference between the cost estimates of the
two cohorts. In both MSD’s and non-MSD, inpatient facility expenditures were the
highest ($33,461.85; $30,798.62) followed by prescription drug expenditures
($26,384.35; $25,651.44), and office-based expenditures ($16,338.80; $16,834.81). The
emergency room expenditures and the office-based chiropractor expenditures made
smaller contributions to the overall health care expenditures in both the cohorts.
Similar to the total health care expenditures, expenditures for each service
category was estimated. Table 4 represents the parameter estimates for each IV in both
the cohorts. The mean expenditures for each service category were calculated using the
parameter estimates for each respondent as follows:
Beta coefficient * IV + Intercept = Mean cost under each service category………….. (1)
For example, the total health care expenditures for a respondent were calculated as:
Total health care expenditureindividual = 683.144-595.26*(sex)-447.1*(census region)
+128.31*(marital status)-409.11*(race) +2795.348*(age)-652.576*(education years)
Substituting the values of IVs for each respondent in the above equation, the total health
care expenditures were calculated as:
Total health care expendituresindividual = 683.144-595.26*(2)-447.1*(3) +128.31*(6)409.11*(1) +2795.348*(9)-652.576*(2) = $198,532.31
The sum of the total health care expenditures for all the respondents with MSD’s gave the
total health care expenditures of the MSD’s cohort. Similarly, the total health care
expenditures for the non-MSD cohort were calculated. Table 5 presents the mean
expenditures for the different service categories in the MSD's and non-MSD cohort.
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Table 4. Parameter estimates for different service categories in MSD's and non-MSD cohorts

Independent
variables

Total health care expenditures

Total inpatient facility expenditures

Total prescription drug expenditures

MSD's

MSD's

MSD's

Non-MSD

Non-MSD

42

B

C.I

B

C.I.

B

C.I.

Intercept

683.144

-4906.05
6272.33*

-3503.218

1568.623

Gender

-595.263

-1973.40
782.87

779.481

-4869.27
-2137.51*
446.05
1112.94*

-1919.39 -1238.852 -2210.14
5056.64
-267.56*
-1452.28 11.308
-225.79
267.81
248.40

-1350.303 -1967.59 -1217.826 -1509.15
-733.07*
-926.51*
162.009
9.80
184.832
113.71
314.01*
255.94*

Census
Region

-447.129

-1130.47
235.82

20.798

-141.08
182.67

-337.563

-763.76
88.64

-30.69
199.50

-45.780

-121.20
29.64

-8.524

-43.04
25.99

-754.08
1010.34
-1548.98
730.75

229.673

17.56
441.78*
-762.05
- 199.24*

1.102

-549.45 94.769
551.65
-1075.71 -287.762
347.19

-56.04
245.45
-487.83
87.86

153.642

56.20
251.07*
-192.96
58.82

92.071

46.84
137.30*
-189.10
-69.09*

Marital Status 128.131

-480.639

-592.237

-364.159

B

84.408

C.I.

B

Non-MSD

B

-129.102

C.I.

Education
Status

-409.115

Age

2795.348

1756.50
3834.29

2788.223

2543.21
3042.25*

1078.377

430.00
125.053
1726.07*

803.75
1164.96*

803.876

689.13
918.62*

799.680

745.51
853.84*

Race/
Ethnicity

-652.576

-1493.21
188.06

-16.529

-210.59
177.54

-214.531

-738.96
310.26

-12.93
263.04

-96.367

- 189.21
-3.52*

-43.489

-84.87
-2.10

984.362

-67.068

C.I.

Table 4 (continued). Parameter estimates for different service categories in MSD's and non-MSD cohorts
Independent Total outpatient facility
variables
expenditures

MSD's
B
Intercept

Gender
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Census
Region
Marital
Status
Education
Status
Age

Race/
Ethnicity

C.I.

-73.443 -536.35
389.44
-31.637 -147.55
82.50
22.300 -34.26
78.86
-6.525 -79.59
66.54
-23.767 -118.17
70.64
170.328 84.28
256.36*
-54.852 -124.47
14.77

Total office-based expenditures

Non-MSD

MSD's

B

C.I.

B

60.054

-162.08
282.13
-1.32
107.10
-67.76
-15.13*
-63.05
5.91
-60.94
30.54
117.97
200.56*
-54.338
8.76

666.763 -1322.05
2655.73
-81.632 -572.05
408.79
-108.633 -351.66
134.40
-97.974 -411.91
215.96
27.232 -378.40
432.86
476.368 106.64
846.08*
-216.870 -516.19
82.28

52.891

-41.448

-28.571

-15.199

159.265

-22.788

C.I.

Total ER facility expenditures

Non-MSD

Total office-based
chiropractors expenditures
MSD's
Non-MSD

B

B

B

C.I.

-597.631 -1108.26
-86.99
339.841 215.90
464.49*
-24.550 -85.08
35.89
-12.493 -92.22
66.43
-0.206 -105.39
104.98
494.470 399.51
589.42*
-25.927 -98.47
46.61

C.I.

-37.799 -123.63
48.03
12.176 -8.93
33.43
11.749 1.23
22.24*
-1.109 -14.56
12.52
1.006 -16.45
18.52
7.544 -8.41
23.69
-3.369 -16.27
9.54

B

C.I.

-71.590 -116.20
-27.16*
7.807 -3.03
18.65
0.399 -4.86
5.66
9.700 2.80
16.52*
21.588 12.43
30.74
12.640 4.37
20.90*
-5.983 -12.29
0.325

MSD's

Non-MSD
C.I.

155.700 -172.98
484.38
42.515 -38.53
123.58
2.251
-37.91
42.71
-25.205 -77.08
26/67
-44.374 -111.40
22.60
22.650 -38.44
83.47
-18.687 -68.12
30.74

MSD = Musculoskeletal disorders, Non-MSD = Non musculoskeletal disorders, B = intercept, C.I . = Confidence interval, * Significant at p< 0.05

B

C.I.

73.548 0.022
147.07*
0.456 -17.49
18.40
3.947 -4.76
12.66
-2.624 -14.04
8.79
-11.799 -26.94
3.34
22.783 9.11
37.45*
-0.979 -11.43
9.46

Table 5. Mean expenditures for different service categories in MSD's and non-MSD
cohorts in the 2007 MEPS data.
Mean Expenditures

MSD's

Non-MSD

Total health care expenditures

$91,121.41

$90,234.91

Office-based expenditures

$16,338.80

$16,834.81

Inpatient facility expenditures

$33,461.85

$30,798.62

Outpatient facility expenditures

$3,573.41

$5,252.28

Emergency room expenditures

$493.50

$750.99

Prescription drug expenditures

$26,384.35

$25,651.44

Office-based chiropractor expenditures

$209.97

$603.23

MSD's = Musculoskeletal disorders
Non-MSD = Non musculoskeletal disorders

44

Objective 4: To identify the predictors of total health care expenditures, total officebased expenditures, total outpatient expenditures, total inpatient expenditures, total
emergency room expenditures, total office-based chiropractor's expenditures, and total
prescription expenditures in individuals with MSD's.
Multiple regressions were conducted to identify factors that predicted the health
care expenditures in MSD's. A total of seven regression models were set up to estimate
the predictors of the different service categories and the DVs were the health care
expenditures in each service category. The IV was the presence of MSD’s. Since age,
gender, race, census region, marital status, and education years are categorical variables,
dummy variables for each of these variables were created and added to the regression
model as IVs. Table 6 reports the regression analysis for total health care expenditures in
MSD's. Age (41 to 65 years and 66 years and above), census region of the US (South)
and marital status (under 16 years) were significant predictors of total health care
expenditures for MSD's.

45

Table 6. Predictors of the total health care expenditures for MSD's in 2007 MEPS data.
Model
Variables

Presence of
condition

B

SE

Levels

MSD

CI

Sig. (p)

Lower

Upper

Bound

Bound

5782.46

1423.58

2991.26

8573.66

.000*

-476.99

508.96

-1474.86

520.96

.349

19 to 40

-2428.80

1350.17

-5076.06

218.47

.072

41 to 65

645.71

1436.04

-2169.91

3461.32

.000*

66 and above

4323.47

1534.69

1314.42

7332.56

.005*

Black

-614.08

785.30

-2153.80

925.61

.434

American Islanders
& Native American
Asian

-788.85

2527.80

-5745.15

4167.45

.755

-2179.24

1826.36

-4701.38

342.90

.090

Multiple race

-186.23

1854.98

-3823.68

3450.79

.920

12 years

-342.84

841.33

-1992.43

1306.74

.684

>12 years

564.032

798.84

-1002.25

2130.31

.480

Northeast†
Midwest
South
West

380.38
-1656.14
-1253.22

806.78
729.83
803.44

-1201.48
-3086.23
-2828.51

1962.23
-226.05
322.07

.637
.023*
.119

Separated
Never Married

-155.99
-1145.85

782.83
775.70

-1690.87
-2666.76

1378.88
375.06

.842
.140

Under 16

-3167.32

1429.39

-5969.92

-364.72

.027*

No MSD†
Sex

Male
Female†

Age in years

Race

Education Years

Census Region

Marital Status

0 to 18†

White†

<12 years†

Married†

† Reference group, B: Intercept, SE: Standard Error, C.I: Confidence Interval, R Squared = .072, p< 0.05
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Table 7 reports the regression analysis for total office-based expenditures in
MSD's. Age group (66 years and above) was the significant predictor of total officebased expenditures for MSD's.
Table 8 reports the regression analysis for total prescription drug expenditures in
MSD's. Gender (male), age (41 to 65 years and 66 years and above), and census region
of the US (Northeast) were significant predictors of total prescription drug expenditures
for MSD's.
Table 9 reports the regression analysis for total inpatient facility expenditures in
MSD's. Age (19 to 40 years), census region of the US (south and west), and marital
status (under the age of 16 years) are significant predictors of total inpatient facility
expenditures for MSD's.
Table 10 reports the regression analysis for total emergency room expenditures in
MSD's. None of independent variables were significant predictors of total ER
expenditures for MSD's.
Table 11 reports the regression analysis for total outpatient facility expenditures
in MSD's. Age (41 to 65 years) and census region of the US (Midwest) were significant
predictors of total outpatient facility expenditures for MSD's.
Table 12 reports the regression analysis for total office-based chiropractor
expenditures in MSD's. Age (66 years and above), and marital status (separated) were
significant predictors of total office-based chiropractors expenditures for MSD's.
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Table 7. Predictors of the total office-based expenditures for MSD's in 2007 MEPS data
Model

B

Variables

Levels

Presence of condition

MSD
No MSD†

804.15

Sex

Male
Female†

Age in years

0 to 18†
19 to 40
41 to 65
66 and above

Race

Education Years

Census Region

Marital Status

SE

CI

Sig.
(p)

Lower
Bound

Upper
Bound

501.18

-178.50

1786.80

.109

-80.72

179.18

-432.04

270.60

.652

-161.43
530.05
1348.59

475.33
505.56
540.29

-1092.43
-461.19
289.24

770.55
1521.30
2407.93

.734
.295
.013*

-236.68

276.47

-778.74

305.39

.392

-346.84
-633.26
-354.19

889.93
452.86
653.05

-2091.72
-1521.90
-1634.61

1398.04
254.66
926.23

.697
.162
.588

<12 years†
12 years
>12 years

-4.26
440.17

296.19
281.23

-585.00
-111.24

576.48
991.58

.989
.118

Northeast†
Midwest
South
West

376.79
-280.04
-153.31

284.03
256.78
282.85

-180.10
-783.51
-707.90

933.69
223.42
401.27

Married†
Separated
Never Married
Under 16

-464.82
-362.07
-305.45

275.59
273.08
503.24

-1004.46
-897.51
-1292.12

76.08
173.36
681.20

White†
Black
American Islanders
& Native American
Asian
Multiple race

† Reference group, B: Intercept, SE: Standard Error, C.I: Confidence Interval, R Squared = .191, p< 0.05
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.185
.276
.588
.092
.185
.544

Table 8. Predictors of the total prescription drug expenditures for MSD's in 2007 MEPS
data
Model

B

Variables

Levels

Presence of condition

MSD
No MSD†

205.08

Sex

Male
Female†

Age in years

0 to 18†
19 to 40
41 to 65
66 and above

Race

Education Years

Census Region

Marital Status

SE

CI

Sig. (p)

Lower
Bound

Upper
Bound

165.883

-120.16

530.32

.216

150.12

59.30

33.83

226.40

.011*

-45.99
868.54
1713.17

157.32
167.33
178.83

-354.46
358.45
1362.54

262.48
1014.62
2063.80

.770
.000*
.000*

-31.63
-110.39

91.50
294.55

-211.5
-687.92

147.78
467.14

.730
.708

-211.69
-315.94

149.89
216.15

-505.59
-739.75

82.19
107.85

.158
.144

12 years
>12 years

23.32
120.62

98.03
93.08

-168.89
-61.89

215.51
303.13

.812
.195

Northeast†
Midwest
South
West

95.37
35.14
187.94

94.01
84.99
93.62

-88.95
-131.50
-371.50

279.69
210.78
-4.382

.310
.679
.045*

Separated
Never Married

84.86
43.23

91.21
90.38

-93.98
-133.98

263.71
220.46

.352
.632

Under 16

-96.68

166.56

-423.25

229.89

.562

White†
Black
American Islanders
& Native American
Asian
Multiple race
<12 years†

Married†

† Reference group, B: Intercept, SE: Standard Error, C.I: Confidence Interval, R Squared = .131, p< 0.05
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Table 9. Predictors of the total inpatient facility expenditures in for MSD's 2007 MEPS
data
Model

B

Variables

Levels

Presence of condition

MSD
No MSD†

3949.42

Sex

Male
Female†

Age in years

0 to 18†
19 to 40
41 to 65
66 and above

Race

Education Years

Census Region

Marital Status

SE

CI

Sig.
(p)

Lower
Bound

Upper
Bound

903.29

2178.34

5720.90

.000*

-440.78

322.95

-1073.99

192.42

.172

-1773.46
-764.58
790.48

856.71
911.19
973.98

-3413.07
-2551.15
-1118.26

-53.57
1021.99
2699.80

.001*
.401
.417

-184.07
-109.56

911.18
1603.97

-1161.07
-3254.4

792.91
3033.32

.712
.946

-972.62
527.31

816.22
1177.02

-2572.91
-1780.46

627.73
2835.09

.233
.654

12 years
>12 years

-392.83
-87.41

533.84
506.88

-1439.53
-1081.25

653.83
906.42

.462
.863

Northeast†
Midwest
South
West

-480.68
-1356.50
-1198.53

511.92
462.81
509.80

-1844.41
-2263.93
-2198.09

523.03
-449.07
-198.07

Separated
Never Married

182.58
-927.74

496.72
492.20

-791.32
-1892.80

1156.50
37.30

.713
.060

Under 16

-2344.68

906.86

-4123.00

-566.37

.001*

White†
Black
American Islanders
& Native American
Asian
Multiple race
<12 years†

.348
.003*
.002*

Married†

† Reference group, B: Intercept, SE: Standard Error, C.I: Confidence Interval, R Squared = .181, p< 0.05
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Table 10. Predictors of the total ER facility expenditures for MSD's in 2007 MEPS data
Model
Variables

Presence of condition

B

SE

Levels

MSD

CI

Sig.
(p)

Lower

Upper

Bound

Bound

76.45

88.23

-96.53

249.5

.386

22.87

31.54

-38.97

84.72

.468

19 to 40

59.83

83.68

-104.20

223.90

.475

41 to 65

102.79

89.00

-71.71

277.30

.248

66 and above

74.38

95.11

-112.11

260.87

.782

Black

-10.49

48.67

-105.92

84.93

.829

American Islanders
& Native American
Asian

-84.59

156.67

-391.78

222.59

.589

-56.48

79.72

-212.80

99.83

.479

Multiple race

-60.78

114.96

-286.12

164.71

.598

12 years

15.01

52.14

-87.22

117.35

.773

>12 years

-96.49

49.51

-193.57

.577

.051

Northeast†
Midwest
South
West

1.871
16.55
2.59

50.04
45.20
49.76

-96.17
-72.07
-95.04

99.91
105.19
100.22

Separated
Never Married

-3.42
1.20

48.51
48.07

-98.55
-93.05

91.70
95.47

.944
.980

Under 16

-48.06

88.59

-221.76

125.64

.588

No MSD†
Sex

Male
Female†

Age in years

Race

Education Years

Census Region

Marital Status

0 to 18†

White†

<12 years†

.970
.714
.958

Married†

† Reference group, B: Intercept, SE: Standard Error, C.I: Confidence Interval, R Squared = .050, p< 0.05
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Table 11. Predictors of the total outpatient facility expenditures in 2007 for MSD's
Model
Variables

Presence of condition

B

SE

Levels

MSD

CI

Sig. (p)

Lower

Upper

Bound

Bound

106.81

122.38

-133.72

346.13

.386

-23.69

43.75

-109.48

62.09

.588

19 to 40

-46.69

116.07

-274.22

180.93

.688

41 to 65

152.33

123.45

-89.71

394.38

.217

66 and above

372.57

131.93

113.89

631.25

.005*

Black

-66.28

67.51

-198.64

66.08

.326

American Islanders
& Native American
Asian

-73.75

217.31

-499.84

352.32

.734

-167.62

110.58

-384.44

49.19

.130

Multiple race

-7.57

159.46

-320.24

305.09

.962

<12 years†
12 years
>12 years

44.03
44.48

72.32
68.67

-97.78
-90.16

185.84
179.13

.543
.517

Northeast†
Midwest
South
West

136.798
-11.93
103.08

69.358
62.70
69.07

.809
-134.93
-32.34

272.86
110.94
238.50

.049*
.848
.136

Separated

-64.98

67.29

-196.93

66.96

.334

Never Married

-52.52

66.86

-183.27

78.20

.431

Under 16

-98.51

122.88

-339.44

142.41

.423

No MSD†
Sex

Male
Female†

Age in years

Race

Education Years

Census Region

Marital Status

0 to 18†

White†

Married†

† Reference group, B: Intercept, SE: Standard Error, C.I: Confidence Interval, R Squared = .091, p< 0.05
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Table 12. Predictors of the total office based chiropractor expenditures in 2007 for MSD's
Model
Variables

Presence of condition

B

SE

Levels

MSD

CI

Sig.
(p)

Lower

Upper

Bound

Bound

26.06

26.83

-34.41

85.59

.382

2.79

10.66

-18.12

30.70

.794

19 to 40

19.62

28.56

-35.84

75.12

.488

41 to 65

18.54

30.09

-40.06

70.99

.538

66 and above

79.14

32.16

16.10

142.61

.014*

Black

-13.48

16.45

-45.78

18.72

.413

American Islanders
& Native American
Asian

53.00

52.90

-50.80

156.88

.317

8.40

26.93

-61.20

44.34

.755

Multiple race

-22.40

38.79

-98.61

58.44

.564

12 years

-13.10

17.66

-47.62

21.44

.457

>12 years

-9.88

16.45

-42.67

22.95

.566

Northeast†
Midwest
South
West

-2.07
-19.20
7.53

16.91
15.21
16.80

-35.22
-49.10
-25.41

31.22
10.72
40.21

.903
.209
.654

Separated

-33.74

16.43

-65.91

-1.57

.040*

Never Married

-8.76

16.2

-40.63

8.23

.589

Under 16

-11.98

29.65

-70.71

46.70

.690

No MSD†
Sex

Male
Female†

Age in years

Race

Education Years

Census Region

Marital Status

0 to 18†

White†

<12 years†

Married†

† Reference group, B: intercept, SE: Standard Error, C.I: Confidence Interval, R Squared = .080, p< 0.05
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Objective 5: To calculate a national estimate for the total incremental health care
expenditures of MSD's compared to the non-MSD cohort.
Incremental cost analysis is a decision-making technique used to determine the
true cost difference between alternatives. To calculate a national estimate for the
incremental health care expenditures for treating MSD's, mean cost of individuals with
non-MSD diagnosis was conducted. A separate dataset of individuals with non-MSD
was created and a linear regression model was run, similar to the MSD’s cohort. The cost
of treatment under different service categories was then calculated. The incremental
difference was calculated by subtracting the mean total cost per service category of nonMSD from that of the MSD’s.
The regression model used is as follows:
Expenditure = Intercept + B1Presence of MSD + B2Age + B3Gender + B4Race +
B5Marital Status + B6Census Region + B7Education years + E
For a national estimate for each service category, the mean incremental difference was
multiplied by the prevalence of MSD's cases for the year 2007:
National Estimate = Incremental cost of MSD x Prevalence of MSD
The 2007 estimate was inflated to present day value (2011) by multiplying the
2007 costs estimate with the 2011medical inflation rates reported by the BLS. 37 The
proportional increase in 2011 costs was calculated using the formula:
2011 costs =2007 costs*(2011 index value /2007 index value) =2007 costs *
(400.258/351.054)
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The prevalence of MSD's was assumed to be the same for 2007 and 2011. Table 13
presents the mean incremental cost difference and the national estimates for different
service categories for both 2007 and 2011.
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Table 13. Incremental and national cost estimates for MSD's compared to non-MSD
Service category

Mean expenditures
MSD's

Incremental cost

Non-MSD

2007

Inflated 2011 value

National Estimates
2007

Inflated 2011 value
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Total health care expenditures

$91,121.41

$90,234.91

$886.49

$1010.74

$30.25 billion

$35.61 billion

Total emergency room expenditures

$493.50

$750.99

$257.49*

$293.57

$8.71 billion

$10.34 billion

Total office-based chiropractor expenditures

$209.97

$603.23

$393.27*

$448.32

$13.40 billion

$15.79 billion

Total office-based expenditures

$16,338.80

$16,834.81

$496.01*

$565.45

$16.92 billion

$19.92 billion

Total prescription drug expenditures

$26,384.35

$25,651.44

$732.91

$835.51

$25.01 billion

$29.43 billion

Total outpatient facility expenditures

$3,573.41

$5,252.28

$1678.87*

$1913.91

$57.29 billion

$67.43 billion

Total inpatient facility expenditures

$33,461.85

$30,798.62

$2663.22

$3036.06

$90.80 billion

$106.97 billion

The national prevalence of MSD's in 2007 was 11.3%. The prevalence rate was assumed to be the same in 2011.
US Population in 2007 = 302,000,000
US Population in 2011= 311,811,000
* Negative increment for MSD's
Inflated value calculated by multiplying the costs with a ratio of 2011 index value (400.258) and 2007 index value (351.054)

CHAPTER FIVE
DISCUSSION AND CONCLUSIONS

This study utilized the HC and the MPC from the 2007 MEPS data to study the
demographics, prevalence estimates, and cost estimates of MSD’s. Specifically, the
study estimated the total health care expenditures in MSD’s and the costs of different
service categories including total inpatient facility expenditures, total outpatient facility
expenditures, total prescription drug expenditures, total office-based chiropractors
expenditures, total office based expenditures, and total emergency room facility
expenditures. The study also estimated the incremental costs of MSD’s compared to nonMSD and identified the predictors associated with these cost estimates.
In 2007 MEPS data, 94,246 individuals were surveyed and this translated into a
weighted national population of 301,309,149. Of the total weighted population, 11.3%
had a primary diagnosis of MSD's. As per our study, in 2007 approximately 34.8 million
people suffered from a primary musculoskeletal condition. Since MEPS data only
provides primary diagnoses, this prevalence rate is an underestimate and will likely be
higher if both primary and secondary diagnosis for MSD's are considered.
Very few studies have reported the prevalence data for MSD’s in the US. Yelin et
al. (1996) reported that 4,161 individuals (unweighted) had a primary or secondary
musculoskeletal conditions with 53.935 million individuals nationwide (20.1% of the
population) reporting at least one musculoskeletal condition. 32 Another study using the
2004-2005 National Health Interview Survey (NHIS) estimated a total of 110.8 million
57

individuals with a primary or a secondary musculoskeletal condition. 3 In yet another
MEPS data study, the prevalence of MSD in the US population was reported as 10.6% in
2006.39
Based on the data from the last decade, there seems to be an upward trend in the
prevalence of MSD’s in the US. One of the most commonly cited reason for this trend is
the increase in the aging population in the US. 3 Other reasons that are responsible for the
increase in prevalence include the burden of other chronic disorders, life style changes,
and increasing life expectancy.3 Contrary to the popular belief that MSD’s are common
in aging population; in this study, high prevalence was also seen in the age categories of
0-18 years and 19-40 years. Some potential explanations for the increased prevalence in
these age groups could be due to the nature of work activities that require physical stress
(e.g., sports, heavy labor intensive jobs).3 Thus, the prevalence of MSD's in the elderly
seem to be a chronic condition and is also prevalent in the young adults, although as an
acute condition.
The demographic analysis of the 2007 MEPS data revealed a higher prevalence of
MSD’s in females (52.1%) compared to the males (47.9%). This finding is consistent
with those reported by other studies. Wijnhoven et al. (2006) presented an overview of
gender differences in musculoskeletal pain and presented data obtained from two general
population-based prospective surveys administered in a Dutch population. Study
reported that females experienced MSD’s at a higher rate (45%) than males (39%). 39
Based on epidemiologic data, females tend to have higher incidences of rheumatic
conditions than males.39 A number of reasons are cited for the higher prevalence in
females including hormonal changes, genetic differences, and lifestyle differences
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between the two genders. Females experience both exogenous changes in hormonal
levels (e.g., due to oral contraceptive pill) and endogenous changes (particularly related
to menstruation and pregnancy history). The genetic influence could either be direct i.e.,
influence of genes on sex chromosomes or indirect i.e., microchimerism. 40
The data was analyzed to study the prevalence of MSD’s by the census region of
the US. A majority of individuals with MSD’s were from the South (38.6%) followed by
the West (26.9%), Midwest (20.4%), and Northeast (14%). A number of reasons can
possibly explain this trend. The higher obesity rates in the southern part of the US are
considered a major contributor to the increased prevalence of MSD's in this region. 41
Genetic reasons are also cited for the increased incidence of MSD's.42 Hundreds of genes
are involved in making proteins that protect muscle fibers from damage. Muscular
dystrophy leading to MSD's occurs when one of these genes is defective. Each form of
muscular dystrophy is caused by a genetic mutation that's particular to that type of the
disease. Many of these mutations are inherited, but some occur spontaneously in the
mother's egg or in the developing embryo.42 Environmental influence is another major
factor responsible for MSD's cases. Workers in the colder region have high prevalence of
MSD's, especially of the lower back and shoulders. Cold weather has shown to increase
the risk of muscle strain resulting in tense muscle tissues, which are susceptible to
injuries.43
In the literature, MSD’s are commonly reported as the disease of the “Whites”
since the prevalence is always higher in Whites than in other races.44 Consistent results
were seen in our study (Whites -75.1%; Blacks - 17.1%) although we have to be careful
in drawing our conclusions based on the surveyed individuals given the over sampling of
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Whites in 2007 MEPS data. However, since the data was adjusted with sample weights,
we are confident that the weighted results are much more reflective of the national
prevalence data.
The data was analyzed to study the prevalence of MSD’s by marital status.
Majority of the individuals with MSD’s were married (38.2%) and this observation can
be explained by the fact that married workers have several non-occupational
responsibilities such as cleaning, washing, taking care of their spouse and children, to
name a few, which exposes them to more ergonomic stressors than those who are not
married.45
The study also analyzed the prevalence of MSD's based on the years of education
of an individual. The study results are similar to the previous findings that individuals
with 12 years or less of education had the highest prevalence of MSD's.46 This is
primarily due to the fact that individuals with less education are less aware of the MSD's
and the factors that lead to MSD's. Also, poor understanding of the disease and its
processes has been observed in individuals who are less educated. 46 Additionally, those
with less education are more likely to be involved in labor-intensive jobs.47
The study estimated the mean total health care expenditures at $91,121.41 with an
estimated incremental societal burden of $30.25 billion in the US in 2007. The high costs
of MSD’s could be attributed to the growing number of aging population and younger
individuals affected by the condition and the use of biologics in the treatment of MSD's.
For treating individuals with MSD's, both invasive and non-invasive procedures are
conducted. Some procedures like hip replacements or joint surgeries are extensive and
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involve extended care at a live-in facility. Also, the annual medication expenditures for
treatment of RA and AS with the new biologic drugs can be as high as $15,000 - $20,000
per patient which significantly increases the costs burden of the disease.40 Additionally,
if individuals with both primary and secondary diagnosis of MSD’s condition are
considered and the indirect cost (e.g., loss in productivity) is calculated, the overall
burden of MSD’s on the society will be enormous.
The study compared the different service category costs in MSD’s with those of
non-MSD. From our analysis, we found that there is a significant burden of MSD's due
to the inpatient expenses. Analysis suggested that there was a mean $2,663.20
incremental burden of MSD over non-MSD individuals. Taking into account the total US
population for the year 2011, the overall annual expenditures due to inpatient facility
expenditure of the MSD's in the US was approximately $106.97 billion. A study by
Osborne et al. suggested that MSD's was responsible for the 6th largest inpatient visits in
the US followed by renal dialysis, general surgery, obstetrics, gastroenterology, and
general medicine.48 As suggested earlier, a possible reason for increased inpatient
expenditures could be due to the use of invasive and non-invasive procedures such as
joint surgeries, corticosteroid injections, anesthetic injections, and dry needling etc.49
Secondly, with the increase in aging population, there is an increased utilization of these
procedures, which leads to increased total inpatient facility expenditures for MSD's.
Preventive steps such as early detection of the disease and screening programs, laboratory
tests like alkaline phosphatase and RA factor test are needed to limit the inpatient facility
cost as the number of individuals with MSD’s is increasing and the demand for inpatient
services are growing. For example, individuals should be regularly screened using
61

techniques like x-rays, ultrasound, and MRI for symptoms related to MSD's and should
be treated at a level where inpatient procedures are not required. These screening
procedures, although expensive, have been very effective in lowering the cost of
treatment for disease conditions like diabetes mellitus in the long run.28 For example, in
diabetes, glycosylated hemoglobin (HbA1c), foot ulcer, smoking status, and retinopathy
are assessed on a regular basis which helps control the disease and also keeps the disease
management costs in control.
Study results also showed that the mean expenses for total outpatient facility for a
non-MSD were higher ($1,678.87) than the mean expenses for MSD's. This is consistent
with previous studies that reported that the total outpatient facility charges were higher
for non-MSD compared to MSD's.44 Individuals suffering from MSD's require inpatient
care and do not use outpatient care as much due to the nature of the disease condition.
Prescription drug utilization was higher in MSD's. Kaiser Foundation reported
that around 10% of the total health care costs was due to prescription drugs alone.50 It
was suggested that the overall prescription costs has decreased, although there was an
increase in the prescription costs in chronic conditions, especially in the aging population.
Our study findings are consistent with those reported by Kaiser Foundation and
demonstrates an increasing prescription drug utilization in MSD's.46 Another reason for
the increased prescription drugs costs in MSD’s is the enormous costs of the new
biological treatments that was introduced in the early 2000.
Study result indicated that office-based facility expenditures are lower for MSD's
as compared to non-MSD. Office-based services include any infusion expenses and other
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services administered to the patient in the physician's office. For example, biologics such
as Remicade® is administered as an infusion in a physician’s office. These expenditures
are lower for MSD's due to the fact that MSD's require more inpatient care and mostly
use prescription drugs to control their symptoms.
Studies have shown that chiropractic care is a cost-effective alternative to the
management of musculoskeletal conditions.51 Chiropractor care is required in the postoperative rehabilitation care and also in treatments which are non-invasive in nature such
as OssaTron Orthotripsy method. Results indicated that there is a higher office-based
chiropractor cost for non-MSD due to injuries resulting from slips, trips, falls, or similar
accidents which are not included under MSD's. Similar to chiropractor expenditures,
study results indicated that total emergency room facility for MSD's was lower ($257.49)
compared to non-MSD. Those with MSD's seldom have disease flare ups which require
them to go to emergency room. Most patients get relief from their relapses by taking
their medications or by visiting the physician. Also, severe cases most likely use the
inpatient facility than the emergency facility.
The national estimates for each service category were compared to previous
estimates for the different service category expenditures. There has been a significant
increase across the different service category costs. Inpatient service expenditures,
prescription drug expenditures, and total health care expenditures have increased
significantly over the last decade and a half. 24 On inflating these expenditures to the
present day estimates (2011 value), the study confirms the significant incremental burden
of MSD’s on the health care system in the US compared to non-MSD.
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Conclusions
There is a significant burden of the MSD's on the US health care system. The
prevalence of MSD in the US was estimated at 11.3%. Approximately, 34,888,246
people were affected by at least one MSD condition in 2007. A majority of individuals
affected by MSD's were whites and were in the southern region of the US. Given the
high prevalence of MSD, the annual incremental direct medical expenditures for the
treatment of MSD's was estimated at $30.25 billion (2007 value) and $35.61 billion
(2011 value).
The annual incremental total health care expenditures associated with MSD's over
non-MSD were $886.49 per person, an increase from $534.5 per person in the year
2006.39 There was a significant cost burden of the MSD's on some health care services.
This cost is still an underestimate of the true cost and could be higher if secondary
diagnosis and indirect costs associated with MSD's are included in the analysis.

Study Implications
The present study improves upon some previous national estimates of MSD’s and
also estimated the major domains of healthcare utilization with predictors of these costs.
The study findings are important for several reasons. The new healthcare reform bill
with increased coverage for uninsured population coupled with an increase in aging
population and increase in the prevalence of MSD’s could potentially result in increased
health care recourse utilization. Thus, there is a need to introduce strategies at the grass
root level which will not only decrease the burden of MSD's on the health care system
64

but also reduce the overall costs associated with the disease. Strategies like disease
screening and increased health literacy will be helpful in decreasing the overall disease
prevalence by early detection and treatment. As discussed earlier, screening techniques
such as the use of x-rays and ultrasound can be helpful in controlling the increase in
disease severity in a timely manner. There have been increased cases of MSD's among
individuals less than 18 years of age. There is a need to implement programs like health
awareness among children about the causes of MSD's. For reducing resource utilization
among elderly individuals suffering from chronic conditions, home health model could be
implemented, that will help in decreasing the emergency room and inpatient facility
expenses, and would also provide better care to the individuals.
This study will help the managed care organizations and payers such as Medicare in
understanding the increased burden of MSD's. The systematic assessment of MSD's and
their associated incremental costs to the society is essential in increasing the awareness of
decision makers to implement intervention strategies that are effective in lowering the
disease incidence and in reducing the overall cost of disease management. The
implementation of disease management programs like home health and screening for
early disease detection and the use of cost-effective treatments will help payers control
the rising costs of MSDs, including the cost of MSD-related prescription drugs.

Study Limitations
The present study has some limitations: First, the limitations associated with a
retrospective database are applicable to this study. Some of these limitations include
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dependency on previously recorded data in the database, whose quality may be limited by
systematic or recorder bias, data coding-recoding errors, incomplete data, data quality,
and confounding factors. Second, we identified individuals with MSD's and non-MSD
based on the self-reported medical conditions of the survey respondents. Based on the
accuracy of the self-reported data, there is a possibility of f over-estimating or underestimating disease prevalence. Third, the analysis only included direct medical expenses.
Indirect cost such as loss of productivity transportation expenses, lost wages among
family members, caregiver burden, etc., were not included in the estimation of the overall
expenditures calculation. Fourth, the study included only patients with the primary
diagnosis of MSD's, since MEPS does not provide secondary diagnosis. Finally, the low
R-squared that is observed in the regression analyses should be considered. Nonexperimental cross-sectional studies obtained from a panel or longitudinal data generally
present a low R-squared in the estimation of the DV. The reason for the low R-squared
may stem from the nature of the epidemiological data (longitudinal or panel) i.e., it is a
combination of cross-sectional and time-series datasets, and the R-squared reported from
an analysis using this type of data is rather “cross sectional-like”. For instance, if one
compares person A’s outcomes with his/her own outcomes at different times (time-series)
one can certainly explain much of the variation with just a few variables. However, if
one compares person A’s outcomes with person B’s outcomes (cross-sectional) those
same few variables will explain less, if any, of the variation. Thus, a cause for concern
on a low R-squared depends on the type of dataset employed and the model.
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